Xeris Biopharma Holdings Stock Price, News & Analysis

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of 16,000 non-qualified stock options to 38 new employees as part of its Inducement Equity Plan on January 27, 2021. This plan is designed to attract individuals not previously employed by Xeris, with options vesting over four years based on continued employment. Xeris specializes in developing ready-to-use injectable and infusible drug formulations through its advanced technology platforms, offering potential cost-saving and user-friendly solutions in the pharmaceutical market.

Xeris Pharmaceuticals (Nasdaq: XERS) announced that CEO Paul R. Edick will present at the H.C. Wainwright BioConnect 2021 virtual conference from January 11-14, 2021. The presentation will provide an overview of the company's innovative drug technologies, including its proprietary XeriSol™ and XeriJect™ platforms that offer stable, ready-to-use formulations. A webcast will be available starting January 11 at 6:00 a.m. E.T. on the company's website.

Xeris aims to simplify administration of vital therapies, benefiting patients and healthcare systems.

Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) announced the grant of non-qualified stock options for 38,250 shares and restricted stock units for 35,100 shares to 7 new employees under its Inducement Equity Plan as of December 30, 2020. The options will vest over four years, either with 25% vesting after one year or 36% after 18 months, while the restricted stock units will vest in equal annual installments. This plan aims to incentivize new hires in line with NASDAQ Listing Rules. Xeris focuses on developing ready-to-use injectable medications using advanced formulation technologies.

Xeris Pharmaceuticals (Nasdaq: XERS) has entered an exclusive distribution agreement with Megapharm Ltd. for the commercialization of its Gvoke® (glucagon injection) in Israel and the Palestinian Authority. Gvoke® is recognized as the world's first ready-to-use liquid glucagon for treating severe hypoglycemia in diabetes patients aged 2 and above. Megapharm will oversee product registration and marketing, while Xeris manages manufacturing and regulatory support. Gvoke® is expected to be available in Israel in 2022, with early access for named patients starting in early 2021.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) received a positive Opinion from the European Medicines Agency’s CHMP for Ogluo™ (glucagon) for treating severe hypoglycemia in diabetes patients. A final decision on the Marketing Authorization Application is expected in Q1 2021. If approved, Ogluo could launch in select European countries in the latter half of 2021. The positive recommendation is based on a Phase 3 study showing comparable efficacy to Novo Nordisk’s GlucaGen® HypoKit®. The study involved 132 adults with type 1 diabetes, indicating no significant safety concerns.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the granting of stock options and restricted stock units to 11 new employees under its Inducement Equity Plan. On November 25, 2020, a total of 18,000 stock options and 70,200 restricted stock units were awarded, which vest over four years contingent on continued employment. This plan, designed for new hires, aims to attract and retain talent while adhering to NASDAQ rules. Xeris specializes in developing ready-to-use injectable and infusible therapies aimed at simplifying patient administration.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) reported financial results for Q3 2020, noting a net loss of $16 million ($0.35 per share), an improvement from a loss of $32.8 million in Q3 2019. Gvoke, a ready-to-use glucagon auto-injector, achieved $9.4 million in sales for the quarter, showing a 140% increase in prescriptions. R&D expenses decreased to $3.9 million, while SG&A rose to $16.5 million due to increased personnel costs. As of September 30, 2020, Xeris had $141.7 million in cash. The company anticipates key regulatory decisions in 2021.

Xeris Pharmaceuticals (Nasdaq: XERS) will release its Q3 2020 financial results on November 9, 2020, prior to the U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss financial and operational outcomes. As a specialty pharmaceutical company, Xeris focuses on innovative drug formulations to improve therapy administration. Notably, its proprietary platforms provide room-temperature stable injectable therapies, streamlining use for patients and healthcare providers.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) has granted non-qualified stock options totaling 36,250 shares to 15 new employees as part of its Inducement Equity Plan. This plan provides equity awards to individuals not previously employed by Xeris, incentivizing them to join the company. The stock options will vest over four years, with various vesting schedules based on continued employment. Xeris leverages innovative technology to simplify injectable and infusible drug formulations, with its first commercial product being Gvoke®.